Clinical trials: Metabolism and Excretion
Hypercholesterolemia, Diabetes Insipidus
Effect of Statin Treatment on Urinary AQP2 (uAQP2/01)
The purpose of this study is to test the hypothesis that the function and/or regulation of urinary aquaporin 2 in hypercholesterolemic humans is affected by standard statin therapy, as compared with diet alone
- Trial name
- uAQP2/01 (NCT02523001)
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- University of Bari
Type 2 Diabetes Mellitus, Proteinuria
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas
Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03983551
- Testing
- Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
- Volunteers
- 101 people
- Sponsor
- Changhua Christian Hospital
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
- Trial name
- NCT02489513
- Testing
- [14C]-AG-120
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Healthy Male Subjects
Study of RPT193 in Healthy Adult Male Subjects
Phase 1, open-label, absorption, metabolism, excretion, and mass balance study.
- Trial name
- NCT06087978
- Testing
- 14C RPT193
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Pulmonary Disease, Chronic Obstructive
A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects
Batefenterol (GSK961081) is a bifunctional bronchodilator that is being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02663089
- Testing
- [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Advanced Malignancies, Solid Tumors
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
- Trial name
- NCT00426140
- Testing
- Patupilone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Male Subjects
A Human AME Study for Omaveloxolone
This study will assess the pharmacokinetics (PK), mass balance, metabolite profiles, and rates and routes of elimination of [14C] omaveloxolone and derived metabolites following administration as a single 150 mg (containing…
- Trial name
- NCT03931590
- Testing
- [14C]-Omaveloxolone
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Volunteer Study, Healthy Adults
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma.
- Conditions
- Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
- Trial name
- NCT07660731
- Testing
- PF-08103402, Midazolam
- Where
- 2 sites in United States, Belgium
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Oat Phenolics Bioavailability
A diet rich in whole grain is inversely associated with cardiovascular disease risk and this benefit could be partly attributed to the phenolic acid content of whole grains.
- Trial name
- NCT02574039
- Testing
- Oat bran, refined grain
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Reading
Healthy
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers
Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C] Prucalopride Succinate in healthy male volunteers aged 18…
- Trial name
- NCT01807000
- Testing
- Radiolabeled Prucalopride Succinate
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteer
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948.
- Trial name
- NCT06691828
- Testing
- NX-5948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Healthy Volunteers
Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.
This study will investigate the absorption, distribution, metabolism and excretion (ADME) of 14C PF-06651600 and characterize plasma, fecal and urinary radioactivity and identify any metabolites, if possible, of 14C PF-06651600…
- Trial name
- B7981011 (NCT03929510)
- Testing
- 14C-PF-06651600, 14C-PF-06651600 IV, PF-06651600
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tumors
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664
- Trial name
- NCT00435669
- Testing
- Brivanib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Bristol-Myers Squibb
Asymptomatic Hyperuricemia
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat +…
- Trial name
- NCT03316131
- Testing
- Verinurad, Febuxostat, Dapagliflozin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Coronary Heart Disease
Addition of Phytosterols to a Low Phytosterol Diet
Studies have shown that phytosterols will lower LDL cholesterol. Typical diets can contain between 250 to 500 mg of naturally-occurring phytosterols.
- Trial name
- phyteaux-I (NCT00860054)
- Testing
- Different amount of phytosterols are added into diets
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Advanced Solid Tumors, Pharmacokinetics of 14C-labeled Gilteritinib
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled gilteritinib, in particular, the routes of excretion and extent of metabolism of gilteritinib following administration of a single dose of 14C-labeled…
- Trial name
- NCT02456883
- Testing
- gilteritinib, 14C-labeled gilteritinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.
The purpose of the study is to investigate the absorption, metabolism, and excretion of 14C JNJ-38518168 in healthy adult male participants after a single oral dose of 30 mg 14C JNJ-38518168.
- Trial name
- NCT01970020
- Testing
- JNJ-38518168
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of…
- Trial name
- NCT04680273
- Testing
- [14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteer
Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers
The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066…
- Trial name
- NCT01082380
- Testing
- PF-02341066
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gaucher's Disease Type I
A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants
Objectives: To determine pharmacokinetic (PK) variables, including absolute bioavailability (F), of Genz-99067, the free base of the L-tartaric acid salt of Genz-112638 as it exists in plasma, after a single intravenous (IV) dose…
- Trial name
- NCT06143904
- Testing
- Genz-112638, [14C]-Genz-112638
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sanofi